- Home
- DX vs BCRX Comparison
DX vs BCRX Comparison
Compare DX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DX | BCRX |
|---|---|---|
| Founded | 1987 | 1986 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | DX | BCRX |
|---|---|---|
| Price | $12.75 | $8.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $14.75 | ★ $20.82 |
| AVG Volume (30 Days) | ★ 4.4M | 4.2M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.76 | $6.00 |
| 52 Week High | $14.93 | $11.31 |
Technical Indicators
Market Signals| Indicator | DX | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 37.55 |
| Support Level | $12.25 | $7.94 |
| Resistance Level | $13.04 | $8.68 |
| Average True Range (ATR) | 0.18 | 0.46 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 17.78 | 23.34 |
Price Performance
Historical ComparisonAbout DX Dynex Capital Inc.
Dynex Capital Inc is a real estate investment trust (REIT) focused on delivering dividends supported by long term returns from investments in mortgage assets backed by U.S. housing and commercial real estate. The Company is internally managed and mainly invests in residential and commercial mortgage-backed securities (RMBS and CMBS), which are Agency securities guaranteed by U.S. government-sponsored enterprises (GSEs). It manages interest rate, prepayment, spread, liquidity, and counterparty risks and operates through one reportable segment investing in MBS funded with repurchase agreements and equity.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.